This article documents evidence-based pharmacologic interventions to promote successful smoking cessation among employees who smoke. The article also highlights supporting evidence for the use of pharmacologic agents to treat tobacco dependence and can guide successful, personalized, pharmacologic smoking cessation interventions in occupational clinical practice. Prescribing clinicians will also find information about the latest research and development of medications to promote smoking cessation, including recently implemented black box warnings by the U.S. Food and Drug Administration.
O ccupational health nurses are front-line clinicians who often implement evidence-based programs in clinical practice. Advanced practice nurses, in particular, serve as leaders within the nursing profession and implement and measure the outcomes of complex programs that aim to improve the health of employee populations in various occupational settings. Many workplace-sponsored clinics are emerging under the "medical home" and workplace medical clinic model with a focus on more comprehensive care and promotion of health and wellness. Occupational health nurses and advanced practice nurses, as prescribing clinicians, are vital members of this workplace health care delivery model and will impact the front-line delivery of occupational health care. Employees who use workplace clinics and medical homes stand to benefit from health care re-tute smoking cessation programs because large groups of adults can be reached (Cahill, Moher, & Lancaster, 2008; Rodriguez-Artalejo et aI., 2003) . Research suggests that smokers who received evidence-based treatment were more satisfied with their care, implying that implementation of evidence-based smoking cessation interventions in the workplace conveys a "we care" message from the employer, potentially increasing employee satisfaction and improving corporate image (Conroy et aI., 2005) . Employers seek input from occupational health nurses when implementing effective evidence-based smoking cessation programs that prepare and support employees during the transition to smoke-free workplace campuses. To be of value to management, occupational health nurses must be knowledgeable about the treatment of tobacco use disorders, including pharmacologic interventions, and call for implementation of effective smoking cessation programs in the clinical practice of occupational health.
Implementing effective, evidence-based smoking cessation programs will aid employers in delivering a population approach to health care emphasizing health promotion and wellness. Programs such as smoking cessation will reduce the prevalence of smoking and the incidence of tobacco use disorders, consistent with the Healthy Workforce 2010 objective of promoting health by reducing tobacco use among adults by establishing comprehensive employee health promotion programs (U.S. Department of Health and Human Services, 200 I). These programs will also support public health promotion by lending strength to the Healthy People 2020 objectives to reduce tobacco use by adults, increase smoking cessation attempts by adult smokers, decrease the proportion of nonsmokers exposed to secondhand smoke, increase tobacco control counseling and screening in health care settings, and increase recent smoking cessation success by adult smokers (U.S. Department of Health and Human Services, 2009).
EVIDENCE TO SUPPORT MULTICOMPONENT SMOKING CESSATION INTERVENTIONS
The literature supports the implementation of complex, multi component interventions (Braverman, Aaro, & Hetland, 2007; Emmons, Linnan, Shadel, Marcus, & Abrams, 1999; Kadowaki et aI., 2004) , including behavioral support that targets individuals undergoing significant life change (Stanton, Lowe, Moffatt, & Del Mar, 2004) , personalized pharmacologic interventions, and global screening for tobacco use, as part of a smoking cessation program that combines complementary interventions to promote long-term smoking cessation among employees (National Institute for Health and Clinical Excellence, 2008; U.S. Department of Health and Human Services, Public Health Service, 2008; U.S. Preventive Services Task Force, 2009) . A review of the smoking cessation clinical guidelines supports the use of global screening, citing recommendations that clinicians identify tobacco use, exposure, and type by using the 5 As-ask, advise, assess, assist, arrange-with all clients (Institute for Clinical Systems Improvement, 2008; Michigan Quality Improvement Consortium, 2007; National Institute for Health and Clinical Excellence, 2008; Registered Nurses Association of Ontario, 2007; U.S. Department of Health and Human Services, Public Health Service, 2008; U.S. Preventive Services Task Force, 2009) . Figure I shows occupational health nurses implementing the 5 As. The use of interventions that include policies, incentives, health care provider advice, and pharmacologic treatment has been validated by Smedslund, Fisher, Boles, and Lichtenstein (2004) .
When advocating for the institution of worksite smoking cessation programs, occupational health nurses can cite clinical guideline recommendations specific to workplace smoking cessation health promotion activities that suggest employers develop a smoking cessation policy in collaboration with staff as one element of an overall smoke-free workplace policy (National Institute for Health and Clinical Excellence, 2007b). Publicizing and making smoking cessation resource information widely available at work, being responsive to individual employees' needs and preferences, providing on-site smoking cessation support, and allowing staff to attend smoking cessation programs during work hours without loss of pay are cited as additional National Institute for Health and Clinical Excellence-recommended actions that employers can take to promote smoking cessation. Figure 2 shows an informational table implemented by occupational health nurses making smoking cessation resource information available to workers as recommended by the NICE guidelines. These guidelines direct employers offering smoking cessation programs to provide one or more interventions that have been demonstrated to be effective, ensure that smoking cessation support and treatment are delivered only by staff who have received appropriate training, and ensure that support is tailored to employees' needs and preferences.
TOBACCO SMOKE-DRUG INTERACTIONS AND EFFECT OF DRUGS ON SMOKING CESSATION
Aside from health care providers giving clear advice to quit smoking, one crucial component is advising smokers of the pharmacokinetic effect of smoking tobacco (or quitting) with other drugs (Kroon, 2007) .
Smoking can affect the metabolism of certain drugs through the hepatic cytochrome P450 system. Employees identified as smokers or those who have recently quit should be screened for potential drug interactions, as numerous drug interactions are associated with tobacco smoke (Kroon, 2007) . These pharmacokinetic drug interactions are caused by products of combustion, or polycyclic aromatic hydrocarbons, found in tobacco smoke, not nicotine (Kroon, 2007) . Polycyclic aromatic hydrocarbons are potent inducers of the hepatic cytochrome P450 isoenzymes I A I, IA2, and possibly 2E I (Zevin & Benowitz, 1999) . Thus, the metabolism of drugs that are substrates for hepatic cytochrome IA2 can be induced in smokers, leading to decreased pharmacologic effect. This translates to higher dose requirements of these drugs in smokers. Likewise, Kroon (2007) advises considering a dosage reduction of drugs that are cytochrome I A2 substrates in smokers who quit.
Caffeine, c1ozapine, olanzapine, fluvoxamine, ta- crine, theophylline, and inhaled insulin are all metabolized by the cytochrome P450 hepatic enzymes (primarily cytochrome lA2) and have the most clinically significant interactions (Kroon, 2007) . Dosage adjustment or selection of an alternate agent may be indicated when considering these drugs for smokers, and the effect of smoking cessation must be considered for smokers who quit or plan to quit while taking these drugs. Of particular concern is the effect of inhaled insulin with tobacco smoke. An increased risk of hypoglycemia occurs in smokers who use inhaled insulin because inhaled insulin peaks faster and reaches higher concentrations in smokers compared to nonsmokers (Kroon, 2007) . Thus, inhaled insulin is contraindicated for smokers or for those who have quit smoking for less than 6 months (Kroon, 2007) .
PHARMACOLOGIC MANAGEMENT OF SMOKING CESSATION IN CONJUNCTION WITH COUNSELING
Research supports the use of combination therapy with counseling and medications (e.g., nicotine replace-AAOHN JOURNAL· VOL. 59, NO.2, 2011 ment therapy) to promote successful smoking cessation among employees. The U.S. Preventive Services Task Force (2009) cites counseling in combination with medications as more effective than either component alone for increasing cessation rates. Employees who participated in an intervention incorporating educational and cessation support sessions, access to nicotine replacement therapy, incentives, quit kits, and other support mechanisms were three times more likely (odds ratio = 3.0, 1.15, 7.83) to quit smoking than those who did not participate, and were more likely to sustain their intention to quit and decrease the intensity and frequency of their smoking patterns (Barbeau et al., 2006) . Several forms of nicotine replacement therapy, sustained-release bupropion (Zyban®, GlaxoSmithKline), and varenicline (Chantix®, Pfizer) have been approved by the U.S. Food and Drug Administration (FDA) and identified as effective first-line agents for treating tobacco dependence in nonpregnant adults.
Two prescription guidelines specifically address pharmacotherapies (National Institute for Health and Clinical Excellence, 2008; U.S. Department of Health and Human Services, Public Health Service, 2008). Nicotine replacement therapy (Nicorette®. Nicoderrn CQ®. GlaxoSmithKline). varenicline (Chantix®), or bupropion (Zyban® ), as appropriate. should be offered in conjunction with advice, encouragement. and support for workers who are planning to stop smoking. The National Institute for Health and Clinical Excellence (2007a) specifically identifies the drug varenicline (Chantix®) as an option for smokers who have expres sed a desire to quit smoking. The National Institute for Health and Clinical Excellence guideline cautions. however, that varenicline (Chantix®) only be prescribed in conjuncti on with a program of behavioral support and within its licensed indications. The FDA warning and regulatory alert is tagged to this guideline through boxed warnings highlight ing the risk of serious neuropsy chiatric symptoms in individuals using this product.
According to the National Institute for Health and Clinical Excellence (2008) and the U.S. Department of Health and Human Servi ces, Public Health Service (2008) guidelines, pharmacotherapy prescribed for smoking cessation should be part of an abstinent-contingent treatment in which the smoker sets a quit date, initiating a commitment to stop. The initial prescription should include a quantity that will last until 2 weeks after the quit date for nicotine replacement therapy. and 3 to 4 weeks after the qu it date for varenicline (Chan -tix®) and bupropion (Zyban®). Only those who have demonstrated. on reassessment, that their quit attempt is continuing should be given a subsequent prescription. allowing the prescriber to monitor for adverse drug events and to ensure that concomitant nicotine use is not ongoing. Risks and benefits should be explained thoroughly to the individual, particularly adolescents (12 to 17 years old), pregnant or brea stfeeding women , and individuals with unstable cardiovascular disorders who wish to use nicotine replacement therapy. Varenicline (Chantix®) and bupropion (Zyban®) should not be offered to individuals younger than 18 years nor to pregnant or breastfeeding women; those with unstable cardiovascular disorders may be offered these two agents, subject to clinical judgment. The guideline recommends avoiding a particular agent for 6 months if the smoker's attempt to quit was unsuc cessful . unless special circumstances hampered the individual's initial attempt to stop smoking. Although forms of nicotine replacement therapy can be combined according to the National Institute for Health and Clinical Excellence guideline, nicotine replacement therapy, varenicline, and bupropion are not recommended in any combination.
Interestingly. the U.S. Department of Health and Human Service s, Public Health Service (2008) guideline supports the use of combination medications (nicotine patch plus sustained-release bupropion , strength of evidence A). Options should be discussed with the individual. taking into account the individual's personal preferences, contraindications, potential pharrnacokinetic drug interactions (hepatic cytochrome P450), previous experiences with smoking cessation aids, and the likelihood that the individual will follow the course of treatment (National Institute for Health and Clinical Excellence, 2008).
SPECIFIC PRESCRIBING GUIDELINES BY SMOKING CESSATION AGENT
Specific pharmacologic agents should be offered as clinically appropriate and the risks and benefits thoroughly explained to the worker. Rovina et al. (20 I0) assert that unless contraindicated, pharmacotherapy should be used in all assisted quit attempts. Exploration of agents used in past quit attempts and of concomitant drug use may reveal a potential for smoking-related cytochrome P450 adverse drug events or, alternatively, may uncover past success. Titration of dosages may be required based on history of past drug intolerance and side effects or adverse drug event profiles. Pharmacotherapy may be contraindicated in individuals who smoke fewer than 10 cigarettes daily (Medscape Drug Reference, 20 IOb).
Varenicline
Varenicline is eliminated principally through the urine, with renal elimination primarily through glomerular filtration and active tubular secretion. It does not, as indicated by in vitro studies, induce cytochrome P450 isoenzymes or inhibit major cytochrome P450 isoenzymes (Medscape Drug Reference, 20 lOa). Thus, pharmacokinetic interactions are unlikely with drugs metabolized by or affecting the cytochrome P450 isoenzymes (Medscape Drug Reference, 20IOa).
The common side effects associated with varenicline are nausea, difficulty sleeping, and abnormal, vivid, or strange dreams (U.S. Department of Health and Human Services, Public Health Service, 2008). This agent should be taken after meals and with a full glass of water to combat nausea (Medscape Drug Reference, 20 lOa). The adult dosage is 0.5 mg once daily on days I to 3, 0.5 mg twice daily on days 4 to 7, and I mg twice daily from day 8 through the end of 12 weeks of treatment and should begin I week before the quit date. Titration of the dosage in this way has been shown to reduce drug-related nausea. Temporary reductions or discontinuance may be required if adverse effects become intolerable (Medscape Drug Reference, 20 lOa).
The FDA's Safety Alert and Public Health Advisory concerning the use of varenicline as a smoking cessation agent must be considered when prescribing this agent. The FDA requires that medication guides highlighting the risk of neuropsychiatric symptoms be given to clients receiving these medications (Bliss, 2009) . It is prudent for prescribing providers to not only thoroughly explain these risks, along with supporting benefits, to clients, but also ensure that clients' next of kin or designated significant others or caregivers are aware of the potential for neuropsychiatric symptoms and steps to take in notifying the prescribing practitioner if they occur.
Bupropion
The relationship between bupropion's plasma concentrations and its metabolites has not been clearly estab-AAOHN JOURNAL· VOL. 59, NO.2, 2011 lished, but it appears that the drug is metabolized extensively, probably by the liver (Medscape Drug Reference, 20IOc). Smoking alters the metabolism of certain drugs through the hepatic cytochrome P450 system. Data from animal studies suggest that bupropion may induce hepatic microsomal enzymes, potentially altering the pharmacokinetic response of drugs that are also metabolized by the cytochrome P450 system (Medscape Drug Reference, 20IOc) . Although the manufacturer states that clients can receive transdermal nicotine concomitantly with bupropion, little is known about the effect of tobacco smoking (polycyclic aromatic hydrocarbons) with the use of bupropion. This supports the goal of total smoking abstinence-"not one puff'-within 2 weeks of commencing use of this agent for smoking cessation.
The most common side effects reported with the use of sustained-release bupropion were insomnia (35% to 40%) and dry mouth ( This agent is especially useful for clients concerned about weight gain due to smoking cessation as it has been shown to delay this weight gain (U.S. Department of Health and Human Services, Public Health Service, 2008). Additionally, it may be particularly useful when a concomitant depressive disorder is included in the past or current history of clients attempting to quit, as one sign of nicotine withdrawal is depression (Kramer, 2000) .
It is important to consider the FDA's Safety Alert and Public Health Advisory concerning the use of bupropion as a smoking cessation agent and to appropriately inform clients and their designated next of kin of the associated risks. The clinician should weigh the possible risk of serious adverse drug reactions against the significant health benefits of this agent's use for smoking cessation, including a reduced risk of developing pulmonary disease, cardiovascular disease, and cancer (Medscape Drug Reference,20IOc).
Individuals should begin the drug while they are still smoking, as steady-state plasma concentrations of the drug are not achieved until after about I week. A quit date should be established within the first 2 weeks of therapy, optimally on day 8 of the drug's administration, and frequent monitoring and clinician support should be arranged (Medscape Drug Reference, 2010c). The goal of "not one puff' is optimum on the quit date (eighth day of drug treatment). The initial dose for adults is 150 mg of extended-release bupropion daily for the first 3 days, with subsequent increase for most clients to the usual recommended dosage of 150 mg twice daily (maximum recommended dosage) given 8 hours apart with the first dose in the morning. Doses administered after 4:00 p.m. may contribute to insomnia. Optimal duration of treatment is 7 to 12 weeks; however, individualized, prolonged therapy may be indicated depending on the individual's benefit-risk profile (Medscape Drug Reference,20IOc).
Nicotine Replacement Therapy
When using all forms of nicotine replacement therapy, individuals should be encouraged to abstain totally from using tobacco products. All forms of nicotine replacement provide an alternative source of the drug that is devoid of tars, carbon monoxide. and respiratory irritants, yet reduces symptoms associated with nicotine withdrawal (Medscape Drug Reference. 20 lOa). The efficacy of nicotine replacement therapy for the adjunct treatment of other forms of nicotine dependence (e.g., pipe or cigar smoking, tobacco or dip chewing) has not been established (Medscape Drug Reference, 20IOb); this article solely addresses smoking cessation interventions for cigarette use.
Nicotine Gum. , 2008) . The severity of these symptoms was generally rated as mild; the frequency of symptoms declined with continued use. This method of administration most closely mimics the behaviors of cigarette smoking (handling and inhaling through the mouth), although it is more associated with stigma in some individuals due to the cigarette shape and more obvious use of the oral inhaler and can be locally irritating (Medscape Drug Reference, 20IOb Transdermal systems may potentially provide advantages over buccal nicotine (gum) through reduction in cravings, ease of administration, absence of local oral adverse effects, fewer gastrointestinal adverse effects, less frequent dosing (leading to better adherence), absence of reinforcement of addictive behavior from frequent self-administration of nicotine, and effectiveness across diverse settings and populations (Medscape Drug Reference, 20 lOb).
Combination Agents
Combinations of front-line medications that have been shown to be effective in smoking cessation treatment include nicotine replacement therapy such as the patch with gum or the patch with an inhaler. Additionally, the patch plus sustained-release bupropion is considered an effective combination (U.S. Department of Health and Human Services, Public Health Service. 2008). Those who receive bupropion and nicotine concurrently should be monitored for the development of hypertension (Medscape Drug Reference, 20IOc).
THE FUTURE OF SMOKING CESSATION IN OCCUPATIONAL HEALTH PRACTICE
In addition to policy implementation of campuswide smoking bans, occupational health nurses can expect to see innovative business models as personalized health care pharmacogenomics transitions to the occupational health setting. Personalized health care is described Clinical guidelines can be used in conjunction with validated research to support the pharmacologic management of tobacco dependence in the workplace. Various first-line pharmacologic agents can be used safely in clinical practice in conjunction with other behavioral and support interventions to help employees quit smoking.
Occupational health nurses must increase their knowledge of pharmacogenomics as continued research is translated into clinical occupational health practice.
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Integrating Results From Smoking Cessation Drug Research and Development Into Clinical Occupational
Health Practice as health care that is proactive, rather than reactive, giving individuals opportunities to become more involved in their own wellness; it uses genomics, the identification of genes and how they relate to drug treatment, to tailor the use of medications to each individual's needs (U.S. Department of Health and Human Services, 2010). Researchers are finding gene variants, such as the nicotinic receptor gene CHRNA3, and other single-nucleotide polymorphisms, such as EGLN2 and BDNF, associated with establishing a smoking habit, the number of cigarettes smoked per day, and successful or unsuccessful cessation (Beals, 2010) . Lerman and Berrettini (2003) identified personalized genetic data as a potential method of informing and dosing pharmacotherapy for smoking cessation in combination with a tailored behavioral treatment plan. By integrating genotypic and individualized data into future occupational health practice, clinicians will be better able to devise effective treatment plans, including interventions that eliminate or limit adverse effects. Clinicians will need to advocate for individuals by incorporating gene-based diagnostics and targeted therapies into future clinical guidelines to ensure that personalized health care is being delivered.
